Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
REVENUES
Product revenue, net	$ 1,195,675	$ 216,097	$ 3,091,745	$ 447,719
License and contract	0	0	0	250,000
Total revenues	1,195,675	216,097	3,091,745	697,719
OPERATING EXPENSES
Cost of products sold	129,235	46,908	314,438	130,012
Research and development	4,830,327	4,980,074	15,224,896	13,891,235
Selling, general and administrative	3,537,376	3,009,528	10,220,518	10,163,830
Gain on purchase commitment	0	0	(1,027,322)	0
Total operating expenses	8,496,938	8,036,510	24,732,530	24,185,077
Loss from operations	(7,301,263)	(7,820,413)	(21,640,785)	(23,487,358)
OTHER INCOME (EXPENSE)
Investment income	234,044	1,127	509,006	4,100
Foreign currency (loss) gain	(77,266)	190,719	(352,121)	64,000
Interest expense	(3,434)	(3,019)	(18,523)	(11,423)
Total other income (expense), net	153,344	188,827	138,362	56,677
Loss before income taxes	(7,147,919)	(7,631,586)	(21,502,423)	(23,430,681)
Income tax benefit	0	0	4,674,999	0
NET LOSS	$ (7,147,919)	$ (7,631,586)	$ (16,827,424)	$ (23,430,681)
Basic and diluted net loss per common share	$ (0.63)	$ (0.80)	$ (1.59)	$ (2.46)
Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share (Note 1)	11,432,380	9,552,214	10,613,830	9,537,768